GREY:TSTIF - Post by User
Post by
echo2on Aug 02, 2017 11:52am
208 Views
Post# 26538396
The Story
The Storyremains completely intact. Significant news is that in the next cc we will hear about plans for US production facility to meet demand and have capacity to produce multiples? of the present facility, and that this facility will not require outside financing as its cost will be very manageable. Loss amplified by stock based compensation. And, with time as each scope or instrument is tested and validated for sterilization, this cost of R&D will decline. US is moving to mandate sterilization for these scopes far sooner than previously anticipated, and hospitals and others in the US are calling TSO3 and Getinge for info and orders in anticipation of the upcoming duodenoscope extended claims approval, that only TSO3 can and will have. 80L still on track for 2018, but not early in the year, as they are testing and streamlining costs of components. Will be applying for passthrough unit approval in US shortly, as it is now in EU.. Gotta love the naysayers who lack patience. Despite the buying oportunity, I am only disappointed that the depressed share price means the looming acquisition will be for something in the $6 range, instead of $9 - 10 where it should be. I realize it is not easy to be patient with such an exciting story and such a game changing technology, but patience is what is needed.